Chugai's Avastin Obtains Additional Indication For Non-small Cell Lung Cancer
This article was originally published in PharmAsia News
Executive Summary
Swiss drug maker Roche's Japanese subsidiary Chugai Pharmaceutical announced Nov. 9 that Avastin (bevacizumab) obtained approval for the additional indication of unresectable advanced or recurrent non-squamous non-small cell lung cancer from Japan's Ministry of Health, Labor and Welfare